Article: Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.
2006 Volume 56, Issue 6, Page(s) 772–781
Abstract: ... at the European Helicobacter Study Group (EHSG) Third Maastricht Consensus Conference, with emphasis ... Background: Guidelines on the management of Helicobacter pylori, which cover indications ... of H pylori infection (a) does not cause gastro-oesophageal reflux disease (GORD) or exacerbate GORD ...
Abstract | Background: Guidelines on the management of Helicobacter pylori, which cover indications for management and treatment strategies, were produced in 2000. Aims: To update the guidelines at the European Helicobacter Study Group (EHSG) Third Maastricht Consensus Conference, with emphasis on the potential of H pylori eradication for the prevention of gastric cancer. Results: Eradication of H pylori infection is recommended in (a) patients with gastroduodenal diseases such as peptic ulcer disease and low grade gastric, mucosa associated lymphoid tissue (MALT) lymphoma; (b) patients with atrophic gastritis; (c) first degree relatives of patients with gastric cancer; (d) patients with unexplained iron deficiency anaemia; and (e) patients with chronic idiopathic thrombocytopenic purpura. Recurrent abdominal pain in children is not an indication for a "test and treat" strategy if other causes are excluded. Eradication of H pylori infection (a) does not cause gastro-oesophageal reflux disease (GORD) or exacerbate GORD, and (b) may prevent peptic ulcer in patients who are naïve users of non-steroidal anti-inflammatory drugs (NSAIDs). H pylori eradication is less effective than proton pump inhibitor (PPI) treatment in preventing ulcer recurrence in long term NSAID users. In primary care a test and treat strategy using a non-invasive test is recommended in adult patients with persistent dyspepsia under the age of 45. The urea breath test, stool antigen tests, and serological kits with a high accuracy are non-invasive tests which should be used for the diagnosis of H pylori infection. Triple therapy using a PPI with clarithromycin and amoxicillin or metronidazole given twice daily remains the recommended first choice treatment. Bismuth-containing quadruple therapy, if available, is also a first choice treatment option. Rescue treatment should be based on antimicrobial susceptibility. Conclusion: The global burden of gastric cancer is considerable but varies geographically. Eradication of H pylori infection has the potential to reduce the risk of gastric cancer development. |
|||||
---|---|---|---|---|---|---|
MeSH term(s) | Adult ; Anti-Bacterial Agents/therapeutic use ; Child ; Drug Resistance, Bacterial ; Dyspepsia/microbiology ; Gastroesophageal Reflux/microbiology ; Helicobacter Infections/complications ; Helicobacter Infections/diagnosis ; Helicobacter Infections/drug therapy ; Helicobacter pylori ; Humans ; Lymphoma, B-Cell, Marginal Zone/microbiology ; Stomach Neoplasms/microbiology ; Stomach Neoplasms/prevention & control | |||||
Chemical Substances | Anti-Bacterial Agents | |||||
Language | English | |||||
Publishing date | 2006-12-14 | |||||
Publishing country | England | |||||
Document type | Consensus Development Conference ; Journal Article ; Research Support, Non-U.S. Gov't | |||||
ZDB-ID | 80128-8 | |||||
ISSN | 1468-3288 ; 0017-5749 | |||||
ISSN (online) | 1468-3288 | |||||
ISSN | 0017-5749 | |||||
DOI | 10.1136/gut.2006.101634 | |||||
Shelf mark |
|
|||||
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 160: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.